Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4170.90 +1.5% SILVER 57.17 +2.3% COPPER 6.55 −1.6% OIL 98.06 +3.1% PALLADIUM 1132.25 +3.3% NTR 98.60 −0.9% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.190 −11.6% CLCH 1.08 −1.8% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.175 +2.9% EVI 0.500 +0.0% ADZ 0.120 −4.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.240 −2.0% BAU 0.180 −5.3% TECT 1.68 +1.2% GOLD 4170.90 +1.5% SILVER 57.17 +2.3% COPPER 6.55 −1.6% OIL 98.06 +3.1% PALLADIUM 1132.25 +3.3% NTR 98.60 −0.9% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.190 −11.6% CLCH 1.08 −1.8% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.175 +2.9% EVI 0.500 +0.0% ADZ 0.120 −4.0% MINK 0.075 +0.0% DNO 0.300 +0.0% RRRL 0.150 +0.0% MTT 0.240 −2.0% BAU 0.180 −5.3% TECT 1.68 +1.2%
Regulatory Routine +

Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling

Regulatory Tailwinds Meet Execution Reality as Tilray Consolidates Post-Rescheduling Gains

Executive Summary
  • Tilray Brands issued a statement regarding federal cannabis rescheduling from Schedule I to Schedule III, viewing it as an inflection point for medical research and patient access.
  • The company is actively evaluating participation in the Center for Medicare and Medicaid Innovation (CMMI) pilot program to supply hemp-derived medical cannabis to underserved populations.
  • BrewDog USA launched new product lines including "Juice Club" non-alcoholic beverages and low-alcohol options like "Baby Hazy".
  • Tilray maintains over 7 million square feet of cultivation capacity globally and operates in more than 20 international markets through Tilray Medical.
  • CEO Irwin D. Simon emphasized alignment with science, medicine, and patient needs following the regulatory shift.
Material Impact
  • The federal rescheduling news was previously announced in December 2025, triggering a significant price spike to $19.12; this April update confirms operational positioning rather than introducing new regulatory breakthroughs.
  • Evaluation of CMMI pilot participation is positive but non-binding ("evaluating"), meaning immediate revenue impact remains uncertain compared to the definitive rescheduling announcement made months prior.
  • BrewDog product launches are incremental growth initiatives consistent with previous strategic updates regarding beverage expansion and do not alter the fundamental financial outlook significantly.
  • The stock price has corrected from December highs ($19.12) to current levels (~$10.82), suggesting the market has already priced in regulatory optimism while discounting execution risks; this news reinforces existing expectations without materially changing valuation drivers.
  • Q3 FY2026 results (released April 1, 2026) showed narrowed losses and positive adjusted EBITDA ($10.7M), providing a financial foundation that supports the operational updates in this release.
TLRY · Price
Company Overview
  • Tilray Brands operates as a diversified global cannabis, beverage, and pharmaceutical company.
  • Flagship Project: Tilray Medical platform providing pharmaceutical-grade medical cannabis in over 20 international markets with plans for US expansion post-rescheduling.
  • Beverage Platform: Includes BrewDog acquisition (UK, US, Australia assets) aiming to create a $500M+ global craft beer and beverage platform.
  • Distribution Network: Tilray Pharma operates distribution networks across Europe including Germany and UK partnerships.
  • Operational Scale: Over 7 million square feet of cultivation capacity globally; supports over 400,000 patients internationally.
Read the original news release →

More from TILRAY BRANDS, INC. J